Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5
A Phase IV, Open-Label, Multi-Centre Trial Evaluating the Conversion From Standard Phosphate Binder Therapy to Fosrenol® in Chronic Kidney Disease Stage 5 Patients on Haemodialysis
Sponsor: Shire
Terminated
This study was stopped by the sponsor based on a non-safety related corporate decision
Other terminated trials from Shire
Other Kidney Diseases trials with similar outcome
This PHASE4 trial investigates Kidney Diseases and is currently terminated or withdrawn. Shire leads this study, which shows 8 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jun 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Jun 2021 [monthly]
Terminated PHASE4
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE4
First recorded
May 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shire
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Apeldoorn, Netherlands , Feldkirch Tisis, Austria , Fredericia, Denmark , Genk, Belgium , Hamburg, Germany , Heilbronn, Germany , Holbæk, Denmark , Leipzig, Germany , Lingen, Germany , Linz, Austria and 4 more locations